Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Grows By 25.5%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,390,000 shares, an increase of 25.5% from the January 15th total of 7,480,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is presently 6.6 days.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock traded up $0.16 during mid-day trading on Tuesday, reaching $7.95. The stock had a trading volume of 240,290 shares, compared to its average volume of 1,242,970. The business's fifty day moving average is $8.47 and its 200-day moving average is $7.66. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -53.03 and a beta of 1.22. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.67.

Analyst Ratings Changes

Separately, StockNews.com cut Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 10th.

Institutional Trading of Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC grew its holdings in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $31,000. Natixis acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $49,000. Finally, Blue Trust Inc. grew its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.